OncoMatch/Clinical Trials/NCT06769425
HS-10502 Combination Treatment in Patients With Advanced Solid Tumors
Is NCT06769425 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies multiple treatments for recurrent ovarian cancer.
Treatment: HS-10502 + NHA · HS-10502 + HS-20093 · HS-10502+ Apatinib · HS-10502 + HS-20089 · HS-10502 + Platinum + Bevacizumab · HS-10502 + nab-paclitaxel or Docetaxel or Irinotecan · HS-10502 + Bevacizumab — HS-10502 is a PARP1-specific selective inhibitor. The purpose if this study is to assess the safety, tolerability, pharmacokinetics (PK), and efficacy of HS-10502 Combination Treatment in subjects with advanced solid tumors.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Breast Carcinoma
Triple-Negative Breast Cancer
Prostate Cancer
Gastric Cancer
Biomarker criteria
Required: HER2 (ERBB2) negative
HER2-negative
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: PARP inhibitor
Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies
Cannot have received: B7-H4-targeted therapy
Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies
Cannot have received: B7-H3-targeted therapy
Have received or is currently receiving the following treatment: PARPi/B7-H4/B7-H3-targeted therapies
Cannot have received: cytotoxic chemotherapy
Exception: within 14 days prior to the first dose of study drug
Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
Cannot have received: investigational drug
Exception: within 14 days prior to the first dose of study drug
Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
Cannot have received: anti-tumor traditional Chinese medicine
Exception: within 14 days prior to the first dose of study drug
Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
Cannot have received: other anti-tumor drug
Exception: within 14 days prior to the first dose of study drug
Have received any of cytotoxic chemotherapy drugs, investigational drugs, anti-tumor traditional Chinese medicines or other anti-tumor drugs within 14 days prior to the first dose of study drug; or need to continue these drugs during the study.
Lab requirements
Blood counts
Inadequate bone marrow reserve excluded
Kidney function
Inadequate renal function excluded
Liver function
Inadequate hepatic function excluded
Cardiac function
Cardiological examination abnormality; severe, uncontrolled or active cardiovascular disorders excluded
Inadequate bone marrow reserve or hepatic/renal functions. Cardiological examination abnormality. Severe, uncontrolled or active cardiovascular disorders.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify